Evidence map›Paper›PMID 39140298›Full record

ArticleFuture oncology (London, England)2024

Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe.

Maria Diez-Campelo, Aylin Yucel, Ravi K Goyal, Rohan C Parikh, Elizabeth Esterberg, Maria Jimenez, Martina Sluga-O'Callaghan, Dimana Miteva, Hong Xiao, Ulrich Germing

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maria Diez-CampeloHematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0003-0386-4835
Aylin YucelBristol Myers Squibb, Princeton,NJ 08540, USA.
Ravi K GoyalRTI Health Solutions, Research Triangle Park, NC 27709, USA.ORCID 0000-0003-1632-036X
Rohan C ParikhRTI Health Solutions, Research Triangle Park, NC 27709, USA.ORCID 0000-0003-4516-9996
Elizabeth EsterbergRTI Health Solutions, Research Triangle Park, NC 27709, USA.ORCID 0000-0003-0780-4776
Maria JimenezRTI Health Solutions, Research Triangle Park, NC 27709, USA.ORCID 0000-0003-1626-9867
Martina Sluga-O'CallaghanRTI Health Solutions, 69009 Lyon, France.ORCID 0009-0000-2504-952X
Dimana MitevaCelgene International Sàrl, a Bristol-Myers Squibb Company, 2017 Boudry, Switzerland.
Hong XiaoBristol Myers Squibb, Princeton,NJ 08540, USA.ORCID 0000-0002-0401-9222
Ulrich GermingDepartment of Haematology, Oncology, and Clinical Immunology, University Hospital of Dusseldorf, 40225 Dusseldorf, Germany.

Funding

Bristol-Myers Squibb n/a
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myelodysplastic SyndromesAdultAgedAged, 80 and overCanadaChromosomes, Human, Pair 5EuropeFemaleHematinicsHumansMaleMedical RecordsMiddle AgedTreatment OutcomeUnited StatesHematinicshematologic outcomeslower-risk myelodysplastic syndromesnon-del(5q)real-world datatreatment patterns

Identifiers

PMID39140298
PMCPMC11497946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.